Merger Arbitrage Mondays – January 30, 2017

Merger Activity increased last week with eight new deals announced and two deals closing. You can find all the active deals listed below in our Merger Arbitrage Tool that automatically updates itself during market hours.

We have received requests from several readers about new features and tweaks that they would like to see to the site or the Merger Arbitrage Tool and we try as best as possible to accommodate these requests. When we launched this new site, one of the requests we incorporated was with the ability to filter deals by the type of deal (all cash, all stock, etc.). Today we are launching a new page called Merger Arbitrage Academic Research that lists several academic and industry studies related to this investment strategy. We are also tweaking the Merger Arbitrage Tool to provide links to the original releases when a deal is announced so that you can review those articles or filings directly from the tool instead of having to hunt down the specific Merger Arbitrage Mondays post that referenced the deal. To access this link simply click the + symbol to the left of the deal you are interested in. We have other exciting features in the works that we hope to roll out in the coming weeks.

Deal Statistics:

New Deals:

1. The acquisition of BNC Bancorp (BNCN) by Pinnacle Financial Partners (PNFP) in an all stock deal. Under the terms of the merger agreement, BNC shareholders will receive 0.5235 shares of Pinnacle common stock for every BNC share.
2. The acquisition of Multi Packaging Solutions International Limited (MPSX) by WestRock Company (WRK) for $2.28 billion or $18.00 per share in cash.
3. The acquisition of GenVec (GNVC) by Intrexon Corporation (XON) in an all stock deal. Under the terms of the agreement, GenVec stockholders will receive 0.297 of a share of Intrexon Common Stock in exchange for each share of GenVec common stock. GenVec stockholders will also receive a right to contingent consideration equal to 50% of any milestone or royalty payments received within 36 months after the closing of the transaction under GenVec’s Research Collaboration and License Agreement with Novartis.

Only plus or premium subscribers can access this post. Subscribe today.